KOL Insight Archives | Page 4 of 8 | Report Store

Multiple Sclerosis (MS) KOL Interview – UK, London

In this interview, a UK-based key opinion leader (KOL) discusses typical prescribing habits for disease-modifying therapies (DMTs) in MS. This includes first-generation DMTs and the newer, more potent entrants like Ocrevus, as well as late-stage pipeline DMTs.

KOL Insight

Multiple Sclerosis (MS) KOL Interview – UK, London

Multiple Sclerosis (MS) KOL Interview – UK, Southwest

Multiple Sclerosis (MS) KOL Interview – US, Midwest

HER2+ Breast Cancer KOL Interview – UK

HER2+ Breast Cancer KOL Interview – US, West Coast

2019 ASH Pulse Survey

Type 1 Diabetes KOL Interview – UK

Type 1 Diabetes KOL Interview – US, Midwest

Triple-Negative Breast Cancer KOL Interview – UK

Triple-Negative Breast Cancer KOL Interview – US

Rheumatoid Arthritis KOL Interview – New Jersey, US

Rheumatoid Arthritis Payer Interview – Pennsylvania, US

Rheumatoid Arthritis Payer Interview – UK

Rheumatoid Arthritis KOL Interview – New Jersey, US

Rheumatoid Arthritis KOL Interview – California, US

Rheumatoid Arthritis KOL Interview – UK

Bladder Cancer KOL Interview – US

Datamonitor Healthcare Non-Alcoholic Steatohepatitis (NASH) KOL Interview – US, Reimbursement

Datamonitor Healthcare Non-Alcoholic Steatohepatitis (NASH) KOL Interview – France

Datamonitor Healthcare Non-Alcoholic Steatohepatitis (NASH) KOL Interview – US

Alzheimer’s Disease KOL Interview – US, Northeast

Alzheimer’s Disease KOL Interview – UK

Alzheimer’s Disease KOL Interview – US, South

Pediatric Epilepsy KOL Interview – US, West

Epilepsy KOL Interview – US, West

Datamonitor Healthcare Chronic Heart Failure KOL Interview – US, West Coast

Datamonitor Healthcare Chronic Heart Failure KOL Interview – UK

Datamonitor Healthcare Chronic Heart Failure KOL Interview – Germany

Datamonitor Healthcare Chronic Heart Failure KOL Interview – US, Southwest

Datamonitor Healthcare Hepatocellular Carcinoma (HCC) KOL Interview – UK